Cantor Fitzgerald Reiterates Overweight Rating for X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They currently have a $3.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

X4 Pharmaceuticals Stock Up 0.6 %

XFOR stock opened at $0.27 on Wednesday. The stock’s 50 day moving average is $0.44 and its 200-day moving average is $0.52. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60. The firm has a market capitalization of $47.08 million, a PE ratio of -3.01 and a beta of 0.39. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.07 million. Sell-side analysts expect that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insider Activity at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 over the last three months. 1.62% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently modified their holdings of the stock. Acorn Capital Advisors LLC purchased a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $5,363,000. Geode Capital Management LLC lifted its position in X4 Pharmaceuticals by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company’s stock valued at $2,566,000 after acquiring an additional 49,700 shares in the last quarter. State Street Corp boosted its stake in X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares during the last quarter. Northern Trust Corp increased its holdings in shares of X4 Pharmaceuticals by 2.9% in the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock worth $996,000 after purchasing an additional 37,940 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of X4 Pharmaceuticals by 4.0% in the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after purchasing an additional 24,948 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.